Esperion Therapeutics' (ESPR) "Market Outperform" Rating Reiterated at JMP Securities

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report)'s stock had its "market outperform" rating reiterated by JMP Securities in a research note issued on Thursday,Benzinga reports. They presently have a $7.00 target price on the biopharmaceutical company's stock. JMP Securities' price objective would indicate a potential upside of 236.54% from the company's current price.

ESPR has been the topic of several other reports. HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday. Needham & Company LLC reiterated a "buy" rating and set a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. StockNews.com lowered Esperion Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, November 15th. The Goldman Sachs Group started coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They set an "overweight" rating and a $8.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $7.25.

Esperion Therapeutics Stock Down 5.5 %

ESPR stock traded down $0.12 during midday trading on Thursday, reaching $2.08. 6,577,948 shares of the company's stock traded hands, compared to its average volume of 5,229,817. The company has a market cap of $409.84 million, a price-to-earnings ratio of -3.25 and a beta of 1.03. The company has a 50-day simple moving average of $2.46 and a two-hundred day simple moving average of $2.18. Esperion Therapeutics has a 1-year low of $1.58 and a 1-year high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). The business had revenue of $51.63 million during the quarter, compared to analysts' expectations of $55.44 million. During the same quarter last year, the firm earned ($0.37) EPS. Equities research analysts forecast that Esperion Therapeutics will post -0.28 EPS for the current year.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently made changes to their positions in the company. Rhumbline Advisers raised its position in Esperion Therapeutics by 6,560.6% during the second quarter. Rhumbline Advisers now owns 252,038 shares of the biopharmaceutical company's stock valued at $560,000 after purchasing an additional 248,254 shares in the last quarter. American Century Companies Inc. acquired a new position in Esperion Therapeutics during the second quarter valued at approximately $50,000. Xponance Inc. acquired a new position in Esperion Therapeutics during the second quarter valued at approximately $28,000. Marshall Wace LLP raised its position in Esperion Therapeutics by 94.2% during the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company's stock valued at $9,554,000 after purchasing an additional 2,087,635 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new position in Esperion Therapeutics during the second quarter valued at approximately $148,000. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.